Sign in
Taking people in United StatesNo phase

AI Software Estimates Heart Pumping Strength From a Wearable ECG Patch

Tests AI software estimating heart pumping strength from ECG patch recordings in adults.

Key facts

Who runs it
Peerbridge Health, Inc
Where
Austin, Detroit, Greensboro, Hackensack, New York, Orange, Pasadena, and Weslaco, United StatesSee the 8 sites
Trial code
Registry title
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Status
Recruiting
People taking part
2,000 people, planned
Started
21 Nov 2024
Expected to end
15 Nov 2027
Type of study
Observational
Treatments tested
  • 15-minutes of sitting during COR ECG Acquistion
Record updated
1 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who can wear a Holter heart monitor. It tests whether AI reading a wearable ECG patch can estimate how well the heart pumps.

Age
18 years or older
Sex
All sexes

Main reasons for not taking part

  • Receiving mechanical breathing or circulatory support, or kidney support therapy, at screening or during Visit #1
  • History of poor tolerance or severe skin reactions to ECG adhesive materials
  • Any condition that, in the investigator's opinion, could interfere with following the study plan or be a safety risk

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Able and eligible to wear a Holter monitor

Who cannot take part

  • Receiving mechanical respiratory or circulatory support, or renal support therapy, at the time of screening or during Visit #1
  • Any condition that, in the investigator's opinion, could interfere with compliance with the study protocol or pose a safety risk to the participant
  • History of poor tolerance or severe skin reactions to ECG adhesive materials

Where in United States

  • Texas Cardiac Arrhythmia Research FoundationAustin, United StatesContact: Andrea Natale, MDTaking people
  • Henry Ford HospitalDetroit, United StatesContact: Sacchin Parikh, MDTaking people
  • Moses H Cone Memorial HospitalGreensboro, United StatesContact: Jennifer KnappTaking people
  • Hackensack University Medical CenterHackensack, United StatesContact: Sameer Jamal, MDTaking people
  • Mount Sinai HospitalNew York, United StatesContact: Joslin J Plathottam, MBBS, MPHTaking people
  • Orange County Heart InstituteOrange, United StatesContact: Brian Kolski, MDTaking people
  • Peerbridge HealthPasadena, United StatesContact: Sandeep Gulati, PhDTaking people
  • South Heart ClinicWeslaco, United StatesContact: Frank Mazzola, MDTaking people

About the trial

What the trial wants to find out

This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily activities. The AI software assists clinicians in cardiac evaluations by estimating EF severity, which reflects how well the heart pumps blood.

Read full original descriptionShow less

In this study, EF severity determination will be made using 5-minute ECG recordings collected during a 15-minute resting period with participants seated upright. The results will be compared to EF severity obtained from an FDA-cleared, non-contrast transthoracic echocardiogram (TTE) predicate device. This comparison aims to validate the accuracy of the AI software.

The group in the trial

  • Cohort Breakdown to Power Accuracy Assessments

    The study will enroll up to 2000 participants across Subprotocol A and B, with a predictive total cohort of at least 660 unique participants. Each participant must provide at least one valid paired data point, defined as ECHO results paired with at least 30 minutes of Peerbridge COR™ ECG data, acquired concurrently or within 3 hours of ECHO completion. Enrollment will occur at a minimum of 3 trial sites, with data collection ensuring at least 165 valid paired points per EF Severity category, as determined by the reference ECHO, from different participants. A paired data point is considered invalid if all 5-minute sitting windows during a 15-minute session yield "Not Analyzable" outputs. Participants who do not comply with the protocol or do not yield valid paired data points will be excluded from analysis and study statistics. Trial site investigators may use institutional EMR databases to identify, qualify, and recruit participants from their community patient populations.

    Treatment: 15-minutes of sitting during COR ECG Acquistion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Using COR ECG Wearable Monitor
Plain-language title
AI Software Estimates Heart Pumping Strength From a Wearable ECG PatchGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
1 June 2026